Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial

• Hoofdauteurs: Enzo Errichetti (Auteur), Peter Wolf (Auteur), Saakshi Khattri (Auteur), Patricia Gorecki (Auteur), Megan Miller (Auteur), Jingzhi Jiang (Auteur), Chenglong Han (Auteur), Brian Kirby (Auteur)
• Formaat: Boek
• Gepubliceerd in: Medical Journals Sweden, 2024-09-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Mild psoriasis may be burdensome; if symptoms are inadequately controlled, switching therapy may be warranted. In the Phase 3 NAVIGATE trial, patients with moderate-to-severe plaque psoriasis received ustekinumab for 16 weeks. Patients with inadequate response (Investigator's Global Assessment...